The ability of p53 to function as a tumor suppressor is linked to its function as a transcriptional activator, since p53 mutants that do not transactivate are unable to suppress tumor cell growth. Previous studies identi®ed an activation domain in the amino terminal 40 residues of the protein, a region that binds to several general transcription factors and to some oncogene products. For example, mdm-2, a cellular oncoprotein, binds to this region and represses p53 transactivation. Here we describe a new activation domain within the amino terminus of p53 that maps between amino acids 40 ± 83, and whose residues trp-53 and phe-54 are critical for function both in yeast and in mammalian cells. In vivo studies in yeast show that the new activation subdomain, unlike the previously described, is mdm-2 independent. Both p53 activation subdomains (1 ± 40 and 40 ± 83) require the yeast adaptor complex ADA2/ADA3/GCN5 for transcriptional activation. Moreover, since activation by p53 requires GCN5's enzymatic histone acetyltransferase domain, p53 may regulate gene expression by in¯uencing chromatin modi®cation.
Introduction
The tumor suppressor protein p53 (for a review, see Donehower and Bradley, 1993; Ko and Prives, 1996; Levine, 1993 and references therein) is inactivated in more than half of all human tumors . p53 is a sequence-speci®c transcription factor that suppresses oncogenic transformation (Eliyahu et al., 1989; Finlay et al., 1989) and induces cell cycle arrest (Leonardo et al., 1994) or programmed cell death (Clarke et al., 1993; Lowe et al., 1993a,b) in response to DNA damage.
Three distinct domains have been identi®ed within p53: the acidic aminoterminus is an activation domain (Fields and Jang, 1990; Funk et al., 1992; Raycroft et al, 1990) , the hydrophobic central region contains a sequence-speci®c DNA-binding domain (Bargonetti et al., 1993; Wang et al., 1993) , and the basic carboxyterminus comprises an oligomerization domain (Clore et al., 1994; Jerey et al., 1995; Lee et al., 1994; Sakamoto et al., 1994; Sturzbecher et al., 1992) and a region that regulates DNA binding anity Hupp et al., 1992; Waterman et al., 1995) . Hot-spots for p53 mutations in tumors (Hollstein et al., 1991; Levine et al., 1991) are found predominantly in the central DNA-binding domain.
In addition, p53 can act as a transcriptional repressor, to down-regulate promoters lacking wild type p53 binding sites (Ginsberg et al., 1991; Santhanam et al., 1991; Subler et al., 1992) . The amino terminal transactivation domain of p53 also is required for its inhibitory eects on transcription (Sang et al., 1994; Subler et al., 1994) .
Tumor suppression and transcriptional activation are strongly correlated functions of p53 (Farmer et al., 1992; Fields and Jang, 1990; Funk et al., 1992) . Mutations or deletions in the aminoterminus of p53 coordinately abolish transactivation and tumor suppressor functions. Tumor-derived p53 mutants fail to activate transcription of wild type p53 responsive genes. Furthermore, mdm-2, a cellular oncoprotein which is overexpressed in 30 ± 40% of human sarcomas (Oliner et al., 1992) , owes its oncogenic ability to its ability to conceal the transactivation domain of p53 (Brown et al., 1993; Momand et al., 1992; Oliner et al., 1992) . Biochemical (Lin et al., 1994) and crystallographic analyses (Kussie et al., 1996) of mdm-2/p53 binding show that similar residues in p53 are critical for both mdm-2 binding and transactivation (Lin et al., 1994) . p53 transactivation may operate through direct contacts with components of the general transcription machinery. For example, interactions have been demonstrated between the p53 amino terminus and TATA-binding protein (TBP) (Horikoshi et al., 1995; Liu et al., 1993) , TFIIH (the p62 (Xiao et al., 1994) , ERCC2 and ERCC3 components), as well as the coactivators TBP associated factors [including Drosophila TAFII40, TAFII60 (Thut et al., 1995) and human TAFII31 (Lu and . It is unclear whether these interactions are sucient for transactivation in vivo, or whether additional factors are required.
Although the activation domain of p53 has been mapped to residues 1 ± 40 (Unger et al., 1992) , adjacent sequences contribute to overall p53 activity (Chang et al., 1995) . The region encompassing residues 1 ± 90 of the protein is remarkably acidic and its primary structure is generally similar to other activation domains. For example, the potent activator of herpes simplex virus, VP16, contains an activation domain between residues 413 ± 490, and, like p53, has overall negative charge with bulky hydrophobic amino acids grouped in clusters. The negative charge contributes to overall potency, but the hydrophobic residues are essential for transactivation (Cress and Triezenberg, 1991; Lin et al., 1994; Regier et al., 1993) . Also similar to p53, VP16 has been shown to interact in vitro with general transcription factors TBP (Stringer et al., 1990) , TFIIB (Roberts et al., 1993) and TFIIH (Xiao et al., 1994) .
Full function of VP16 in vivo requires interaction with a dierent class of proteins distinct from basal factors, called adaptors. Adaptors were initially identi®ed by their biochemical (Berger et al., 1990) and genetic (Berger et al., 1992) interaction with VP16. Several genes were cloned using a genetic strategy based on growth inhibition by overexpressed VP16 and they were termed ADA2 (Berger et al., 1992) . ADA3 (PinÄ a et al., 1993) and GCN5 (Marcus et al., 1994) . Mutations in these genes reduced transcription in a promoter selective manner, and this supported a role consistent with activator-speci®c adaptor function. One of these transcriptional adaptors, GCN5, recently has been shown to possess histone acetyltransferase (HAT) activity . Transcriptional activation of certain genes has been attributed to hyperacetylation of aminoterminal tails of core histones (Csordas, 1990; Loidl, 1994; Wole, 1994; Wole and Pruss, 1996) . The ®nding that GCN5 is a transcription factor and also possesses HAT activity supports this hypothesis, and potentially links histone acetylation and transcriptional activation. Indeed, deletion and substitution mutants (Wang et al., 1997) of GCN5 that abolish or reduce its HAT activity are not competent to support full transcriptional activation by VP16.
The striking similarity between the p53 aminoterminus (residues 1 ± 83) and the VP16 activation domain (residues 413 ± 490) prompted us to test the adjacent region to 1 ± 40 for possible activation activity, as well as possible involvement of the ADA pathway in activation by p53. In this report we identify a new activation subdomain (ASD), within p53 residues 40 ± 83. ASDs 1 ± 40 and 40 ± 83 are active in both yeast and mammalian cells. Full function of both ASDs in yeast requires the adaptors ADA2, ADA3 and GCN5. Interestingly, the enzymatic HAT activity of GCN5 is necessary for full activation by p53, suggesting that the transactivation mechanism may include alteration of chromatin structure by p53.
Results

A new activation domain in p53
p53 functions as a potent transactivator (Fields and Jang, 1990 ) both in yeast (Scharer and Iggo, 1992) and in human cells (Unger et al., 1992) . Mapping studies have indicated that the amino terminus of p53 bears a potent activation domain. Studies have focused on aa 1 ± 40, as this region interacts with trans-acting suppressors of p53, such as mdm-2 (Kussie et al., 1996; Lin et al., 1994) . However, there are striking similarities in primary structure between a larger region of the p53 amino terminus (1 ± 83) and the strong activation domain (AD) of herpes virus VP16 (aa 413 ± 490) (Li and Botchan, 1993; Xiao et al., 1994) . It previously has been shown that the VP16 AD contains several independent activation sub-domains that function both in mammalian cells (Cress and Triezenberg, 1991; Regier et al., 1993) and in yeast (Barlev et al., 1995; Silverman et al., 1994) , suggesting multiple redundant or distinct activation pathways whose mechanisms may be evolutionarily conserved. Based on these similarities between p53 and VP16, we tested the activation potential of the 40 ± 83 region of p53.
Initially, the amino terminal 87 residues of p53 were fused to the DNA-binding domain (DBD) of the yeast transactivator GAL4 (Figure 1) . The activation potential of GAL4-p53 1 ± 87 was compared to GAL4-VP16 413 ± 490 (Figure 1 ), which is a potent inducer of a bgalactosidase reporter construct bearing GAL4 binding sites upstream of bacterial LacZ. We found that both GAL4-p53 and GAL4-VP16 exhibited strong activity in yeast (Figure 2, left) .
We then divided the aminoterminal AD domain of p53 into subregions, aa 1 ± 40 and aa 40 ± 83, and fused them to GAL4 DBD (Figure 1) . The results of the bgal assay (Figure 2 , right) showed that both p53 1 ± 40 (ASD1) and p53 40 ± 83 (ASD2) were independent ADs of about similar potency, with ASD1 being consistently slightly more active than ASD2.
The detection of two independent p53 ASDs in yeast prompted us to determine whether these regions also were active in mammalian cells. GAL4-p53 1 ± 87 , and the two derived ASD fusions, were subcloned into mammalian expression vectors and cotransfected into Cos-7 cells with a chloramphenicol acetyltransferase (CAT) gene reporter driven by GAL4 binding sites. GAL4-p53 1 ± 87 was slightly more active GAL4-VP16 413 ± 490 ( Figure 3a) . The relative potency of GAL4-p53 1 ± 40 compared to GAL4-p53 40 ± 83 was similar (Figure 3b ), as was observed in yeast ( Figure 2) .
We then tested the ability of the putative ASDs to activate transcription in the context of full-length p53 protein (Figure 1 ). The ASDs were separately deleted, yielding p53 containing ASD1 alone (p53 D34 ± 78 ) or ASD2 alone (p53 D1 ± 39 ). These were cotransfected into Saos-2 cells, along with a plasmid reporter containing the secreted alkaline phosphatase gene under the control of a p53 binding site. The two subregions activated transcription to similar levels in the full length p53 protein (Figure 4a ), as was seen as GAL4 DBD fusions (Figure 3b ), suggesting that ASD2 is of physiological relevance to the activity of p53.
Residues trp-53 and phe-54 are critical for activity of p53 ASD2
These data indicate the presence of a second activation domain within p53, located between aa 40 ± 83, that is distinct from the previously identi®ed region between aa 1 ± 40. Previous studies of ADs have demonstrated the functional importance of hydrophobic amino acids surrounded by acidic residues (Cress and Triezenberg, 1991; Lienhard-Schmitz et al., 1994) . In ASD1 of p53, mutagenesis of residues leu-22/trp-23 strongly reduces transcriptional activity (Lin et al., 1994) . In ASD2 there are also two consecutive hydrophobic residues (trp53/phe54) surrounded by acidic amino acids. By analogy to the activation domains of VP16 and p53 ASD1, these two hydrophobic residues might be important for transcriptional activity.
Point mutations W53Q/F54S were introduced into ASD2 in either full-length p53 or in p53 D1 ± 39 . As controls, substitutions L22Q/W23S (Lin et al., 1994) p53 adaptor-dependent sub-activation domains R Candau et al were made in ASD1 in either full-length p53 or p53 D34 ± 78 . These constructs were tested for activity in Saos-2 cells. In full-length p53, the double aa substitutions had a deleterious eect, lowering activity sixfold (L22Q/W23S) or threefold (W53Q/F54S) ( Figure 4a ). In the context of aminoterminally deleted p53 proteins, these double aa substitutions abolished transcriptional activity almost completely ( Figure 4a , p53 D34 ± 78,22/23 and p53 D1 ± 39,53/54 ). Thus, the activities of ASD1 and ASD2 were completely dependent on hydrophobic residues L22/W23 or W53/F54S, respectively. We then determined whether W53/F54 were also crucial for activity of p53 ASD2 in yeast. The double aa substitutions were introduced into GAL4-p53. Similar to the observations in mammalian cells, mutation of either L22Q/W23S or W53Q/F54S reduced the activity of GAL-p53 1 ± 83 to a similar low level, approximately 10% of the wild type AD ( Figure  4b ). Moreover, the mutations W53Q/F54S completely abolished activity of GAL4-p53 40 ± 83 ( Figure 4b ). Thus, p53 activation in mammalian and yeast cells requires the same structural elements, suggesting a conserved mechanism.
Mdm-2 functional interaction with the p53 activation domain
The cellular protein mdm-2 binds to the p53 activation domain within aa 1 ± 40 Haines et al., 1994; Lin et al., 1994; Momand et al., 1992) , and inhibits p53 activity apparently by concealing the activation domain from interactions with essential . The strain used was PSY316. GAL4-p53 1-87 was toxic in PSY316, thus, its activity could not be measured in this strain p53 adaptor-dependent sub-activation domains R Candau et al transcription factors (Oliner et al., 1993) . The identi®cation of a second ASD within p53 prompted us to examine whether its activity is also inhibited by mdm-2. Previous experiments have shown that mdm-2 inhibition of the p53 activation domain occurs in yeast, and is speci®c, since VP16 activation is not inhibited by mdm-2 (Oliner et al., 1993) . We therefore cloned mdm-2 into a yeast expression vector and cotransformed it with GAL4-p53 40 ± 83 . The transcriptional activity of GAL4-p53 40 ± 83 was not aected by mdm-2 ( Figure 5 ).
As expected, the activity of GAL-p53 1 ± 40 was reduced in the presence of mdm-2, decreasing fourfold, while the activities of GAL4-VP16 470 ± 490 and GAL4-p53 1 ± 40D13 ± 19 (which deletes critical residues for mdm-2 binding; (Lin et al., 1994) ) were not aected by mdm-2 ( Figure 5 ).
p53 activity in yeast is adaptor dependent
We have previously identi®ed a pathway of activation by VP16 in yeast, which involves functional and physical interaction of the activation domain with transcriptional adaptors (Barlev et al., 1995; Berger et al., 1992) . The apparent structural similarity between ADs from VP16 and p53, suggested that p53 may also require adaptors for full activity, and we therefore tested the dependence of p53 on adaptors.
GAL4-VP16 AD is strongly inhibitory to yeast growth when overexpressed (Berger et al., 1992) , due to apparent`squelching' or titration of key transcription factors (Gill and Ptashne, 1988) . Either speci®c amino acid substitutions in the VP16 AD (Berger et al., 1992) , or genetic deletion of adaptors ADA2 (Berger et al., 1992) , ADA3 (PinÄ a et al., 1993) or GCN5 (Marcus et al., 1994) , relieve this growth inhibition. Since these aa substitutions in VP16 AD or the adaptor gene disruptions also lower transcriptional activation (Berger et al., 1992) , the mechanism of growth inhibition is likely to be related to the normal pathway of activation, and this pathway requires adaptor function. Certain activators, such as the yeast HAP4 activator, are not ADA-dependent, either for growth inhibition or transcriptional activation (Berger et al., 1992) .
Similar to GAL4-VP16, GAL4-p53 1 ± 73 previously has been shown to be growth inhibitory in yeast (Fields and Jang, 1990) . To determine whether such growth inhibition is ADA-dependent, GAL4-p53 containing aa 1 ± 83, was subcloned into an overexpressing yeast plasmid, and transformed into wild type yeast. GAL4-VP16 and GAL4-HAP4 fusions, and the GAL4 DBD by itself served as controls. The transformants were plated on minimal synthetic media and the colony size was evaluated. GAL4-p53 inhibited growth compared to the GAL4 DBD expressing vector. GAL4-p53 was as toxic as GAL4-VP16, and more toxic than GAL4-HAP4 ( Figure 6 ). The same experiment was repeated with isogenic yeast strains bearing disruptions of either ADA2, ADA3 or GCN5. The ADA disruption strains grew worse than wild type when transformed with the GAL4 DBD vector (Figure 6, vector) , because loss of ADAs causes a severe growth defect (Berger et al., 1992; Marcus et al., 1994; PinÄ a et al., 1993) . The eect of GAL4-p53 in the wild type and disruption strains matched GAL4-VP16, since the ADA-de®cient strains relieved growth inhibition by GAL4-p53. In contrast, growth inhibition by over-expressed GAL4-HAP4 was not alleviated by ADA gene disruption ( Figure 6 ).
The relief of GAL4-p53 growth inhibition by ADA disruptions indicated that transcriptional activation by p53 may require ADAs. Therefore we tested the role of ADAs in activation by either p53 or its two independent ASDs. Transcriptional activation by both GAL-p53 1 ± 40 and GAL4-p53 40-83 required ADA2, ADA3 and GCN5, in a similar fashion to GAL4-VP16 470 ± 490 (Figure 7) . p53 ASD1 was less dependent on adaptors than p53 ASD2, since transcriptional activa- versus GAL4-p53 . Cells were cotransfected with 1 mg of the CAT reporter and increasing amounts of plasmid expressing GAL4-p53 1-40 or GAL4-p53 or vector alone (7). Increasing amounts (0.01, 0.1 and 1 mg of DNA) of the expression plasmids were used. The strength of GAL4-p53 1-40 was compared to GAL4-p53 40-83 in ®ve separate experiments, and the data shown are representative p53 adaptor-dependent sub-activation domains R Candau et al tion by GAL4-p53 1 ± 40 decreased 5 ± 10-fold in the absence of adaptors, whereas transcriptional activation by GAL4-p53 40 ± 83 decreased 10 ± 50-fold ( Figure  7 ). Deletion of ADA2 had a less dramatic phenotype, in general, than deletions in ADA3 or GCN5. Taken together, these results indicate that the ASD1 (aa 1 ± 40) and ASD2 (aa 40 ± 83) of p53 require ADAs for full activity. Substitution of either residues leu-14/phe-19 or residues leu-22/trp-23, or deletion of residues 13 ± 19, abolish p53 binding to mdm-2 (Lin et al., 1994) . Since mutations that reduce mdm-2 binding also reduce p53 activation (Lin et al., 1994) , it has been proposed that the same residues are required for both processes. Thus, we wished to test the hypothesis that ADAs might functionally interact with the same region that interacts with mdm-2. Residues 13 ± 19, which are critical for p53/mdm-2 binding (Lin et al., 1994) were deleted from GAL4-p53 1 ± 40 and the resulting fusion protein was transformed into wild type and ADAdisrupted yeast strains. The transactivation activity of GAL4-p53 1 ± 40D13 ± 19 was reduced approximately ®vefold compared to GAL4-p53 1 ± 40 in the wild type strain (Figure 7 , compare left and right panels). Noteably, the remaining activity of GAL4-p53 1 ± 40D13 ± 19 was severely reduced in the ADA deletion strains (Figure 7, right) . Thus, deletion of amino acids 13 ± 19 (which eliminated mdm-2 repression in yeast; Figure 5 ) resulted in a peptide whose transcriptional activity was weaker than wild type and highly ADA-dependent (30 ± 80-fold). This should be compared to the dependence on ADAs of GAL4-p53 1 ± 40 (Figure 7, right) , which decreased in activity 5 ± 10-fold in the disruption stains. For example, in the Dada3 strain compared to wild type, activity of p53 1 ± 40 dropped less than 10-fold, while p53 1 ± 40D13 ± 19 decreased 80-fold.
GCN5's histone acetyltransferase activity is required for transcriptional activation by p53
GCN5 recently has been shown to possess histone acetyltransferase (HAT) activity, suggesting a link between transcriptional activation and histone modi®cation . We previously mapped the boundaries of the HAT domain within GCN5 within residues 95 ± 261 and demonstrated that the HAT domain is required for growth complementation and transcriptional activation by GAL4-VP16 . Since full function of both p53 ASDs 1 and 2 require GCN5, we tested whether the HAT domain of GCN5 was crucial.
A series of deletion mutants within GCN5 ( Figure  8a ; Candau et al., 1997) was used to identify functional domains of GCN5 required for transcriptional activation by each p53 ASD. We tested the ability of the GCN5 peptides to complement transcriptional activation in a gcn5 7 background. Low copy plasmids expressing either GAL4-p53 1 ± 40 or GAL4-p53 40 ± 83 were cotransformed with a b-gal reporter and with plasmids expressing wild type GCN5 or the deletion mutants. The amino terminus of GCN5 was dispensable for transcriptional activation by either GAL4-p53 ASD , since GCN5 95 ± 440 behaved similarly to wild type GCN5 in this assay (Figure 8b and c) . Activation was reduced approximately 50% in the absence of the GCN5 carboxyl terminus (i.e. any of the GCN5 mutants that lack aa 280 ± 440), including the bromodomain (Haynes et al., 1992) , which is present in several transcription cofactors possessing HAT activity (Mizzen et al., 1996; Orgyzko et al., 1996) . GCN5 peptides containing deletions within aa 95 ± 280 were completely defective for activation by either GAL4-p53 1 ± 40 or GAL4-p53 40 ± 83 . Thus, the two ASDs of p53 required the same regions of GCN5 for activation, and, furthermore, the HAT domain (aa 95 ± 261) of GCN5 was crucial for activity of either ASD.
We previously determined the boundaries of the ADA2 interaction domain within GCN5 (residues 253 ± 280) and have shown that GAL4-VP16 activation requires this domain, and therefore, interaction between GCN5 and ADA2 Candau et al., 1997) . Both p53 ASDs also required GCN5/ADA2 interaction, since GCN5 1 ± 261 (which does not interact with ADA2) was not able to promote transcription by either p53 ASD, while GCN5 1 ± 280 (which interacts with ADA2) supported the transactivation functions of either p53 ASD (Figure 8b and c) . Taken together, these results demonstrate that the HAT domain of GCN5, as well as the ADA2 interaction domain, are critical for GCN5's role in transcriptional activation by either p53 ASD.
Discussion
Two adaptor-dependent activation subdomains in the p53 amino terminus
The primary structure of the p53 AD (aa 1 ± 87) is similar to other acidic ADs. Further functional dissection has narrowed the AD to the ®rst 40 amino acids (ASD1), a region rich in acidic and hydrophobic residues (Unger et al., 1992) . However, inspection of the adjacent region (aa 40 ± 83) indicates a similar character, including a tryptophan residue (trp53) surrounded by a hydrophobic/acidic cluster. Thus, the primary structure of the aa 40 ± 83 region, and in particular, the aa 50 ± 60 region, suggested the presence of a second activation subdomain, and our results demonstrate an independent ASD (ASD2) in this region that was active in both yeast and mammalian cells, and whose function required residues W53/F54.
The p53 subregions ASD1 and ASD2 were synergistic in activity, such that the activity of the full AD was greater than the sum of transactivation by the ASDs. Synergism was apparent in both the deletion mutant data for Saos-2 (Figure 4a , *450 units additive vs *1200 units observed), as well as the point mutant data (Figure 4) , in both Saos-2 cells (panel A: *650 units additive vs *1200 units observed) and yeast cells (panel B: *900 units additive vs *4500 units observed). This behaviour was similar to activation domains derived from both VP16 (Barlev et al., 1995) and GCN4 (Drysdale et al., 1995) , since their independent ASDs also exhibit synergistic activity. Thus, as others have observed previously (Emami and Carey, 1992; Ohashi et al., 1994) synergy appears to be a functional consequence of the subdomain structure of activation domains.
The existence of two independent ASDs in p53 may help to explain the low frequency of mutations in the aminoterminus of p53 observed in human tumors (Hollstein et al., 1991; Levine et al., 1991) . Although a correlation exists between the transactivation function of p53 and its ability to suppress growth of transformed cells, activity as low as 15% of wild type p53 is sucient to suppress transformation (Raycroft et al., 1990) . Since either of the two independent p53 ASDs possess signi®cant activity, mutation of both subdomains may be required to reduce transactivation to a level that promotes tumorigenesis.
The two ASDs exhibit functional dierences. Firstly, although the activation potency of the domains was comparable, the two domains were not equally dependent upon the ADAs for activity. Secondly, although both ASDs contain a similar pattern of hydrophobic residues, mdm-2 repressed activity in yeast of ASD1, but not ASD2. The lack of functional interaction between mdm-2 and ASD2 does not exclude the possibility of other, yet unknown, ASD2-binding proteins that negatively regulate p53 function. In any case, since repression of ASD2 in mammalian cells was not tested, the physiological relevance of the absence of functional ASD2/mdm-2 interaction remains to be determined.
It has been suggested that the region that binds to mdm-2 is responsible for activation (Kussie et al., 1996; Oliner et al., 1993) . In our study, deletion of residues in ASD1 that functionally interacted with mdm-2 in yeast (i.e. within aa 13 ± 19; Figure 5 ), yielded a protein (GAL4-p53 1 ± 40D13 ± 19 ) that was partially active and completely dependent on ADAs (Figure 7) . Thus, these experiments suggest that mdm-2 may only partially block functional interactions necessary for activation. Alternatively, ASD1 itself may encompass two activation subdomains, and only one is inhibited by mdm-2. However, since these experiments were performed in yeast, their relevance to the role of p53/ Figure 8 Transcriptional activation by GAL5-p53 ASDs in the presence of GCN5 deletion mutants. (a) Schematic of GCN5. The structure of GCN5 is shown above, including the histone acetyltransferase domain (HAT; , the ADA2-interaction domain (ADA2; Candau et al., 1997) and the bromodomain (Georgakopoulos and Thireos, 1992) (bromo; (Georgakopoulos and Thireos, 1992) ). The extent of the GCN5 proteins included in each deletion mutant is indicated by aa number. (b) Transcriptional activation by GAL4-p53 in the presence of the GCN5 deletion mutants. GCN5 deletion mutants were cotransformed into the GCN5 disruption strain with low copy plasmids expressing GAL4-p53 and reporter pLGSD5. b-gal activity was determined as units per mg of protein. Error bars represent the standard error about the mean from at least two independent experiments, which are representative of multiple experimental trials. (c) Transcriptional activation by GAL4-p53 in the presence of the GCN5 deletion mutants. See b for details p53 adaptor-dependent sub-activation domains R Candau et al mdm-2 interaction in the repression in mammalian cells must be interpreted with caution.
There are also similarities in function between ASD1 and ASD2. Several lines of evidence presented here suggest that both p53 subdomains require the ADA pathway for transcriptional activation. Several ADA genes have been identi®ed and, since ADA proteins have been shown to physically interact in vitro and in vivo Horiuchi et al., 1995) , they apparently form a complex. Consistent with this, ASD1 and ASD2 both required the three ADA genes tested in this study. Both ASDs showed greater dependence on ADA3 than GCN5 or ADA2. Since we have seen previously that ADA3 strongly contributed to the stabilization of ADA2 , the ADA pathway may be most debilitated in the absence of ADA3. Overall, these data suggest that ASD1 and ASD2 require the integrity of the ADA complex.
ADA requirement in yeast was ®rst shown for human herpes virus VP16 and subsequently was shown for other activators, such as yeast GCN4 (Berger et al., 1992) , human NF-kB (Blair et al., 1994a) and the human foamy virus Bel-1 protein (Blair et al., 1994b) . However, some activators are nearly independent of the ADA pathway, such as yeast HAP4 (Berger et al., 1992) . One explanation for these dierences is that ADA-dependent activators physically interact with components of the ADA complex. The fact that p53 also requires the ADA complex, suggests evolutionary conservation of this pathway, underscored by the apparent conservation of ADA2 and GCN5 in humans .
The HAT activity of GCN5 is required for activity of p53 ASD1 and ASD2
Recently, GCN5 has been shown to possess histone acetyltransferase (HAT) activity, suggesting that the ADA complex may function to relieve transcriptional repression by chromatin. We studied the regions of GCN5 required for full activation by p53, and found that the aminoterminal 95 and the carboxyterminal 160 amino acids were dispensable for activation by each p53 ASD. The carboxyl terminal region includes the bromodomain (Haynes et al., 1992) , which has been found in several transcription factors of the coactivator/adaptor class that possess HAT activity (Mizzen et al, 1996; Ogryzko et al., 1996; Yang et al., 1996) . The remainder of GCN5 (aa 95 ± 280), that includes the HAT and the ADA2 interaction region, was essential for p53 activation. These results suggest that acetylation of histones via GCN5 is necessary but not sucient for transcriptional activation by either p53 ASD. The requirement of the region of GCN5 that interacts with ADA2 suggests that GCN5 must be part of the adaptor complex in order to acetylate histones in vivo. This observation is supported by recent biochemical results showing that recombinant GCN5 can acetylate only free histones, but not nucleosomal histones. However, semipuri®ed large (800 kD and 2 MD) yeast complexes containing GCN5 are able to acetylate nucleosomes, but require other ADA proteins (P Grant, L Duggan, S Berger, J Workman, unpublished observations). The pattern of GCN5 domain-dependence of p53 ASDs is similar to the requirements of the VP16 activation domain , suggesting that similar ADA complexes may interact with dierent activation domains.
These data suggest a novel model for gene regulation by p53, that p53-dependent promoters are targeted for histone acetylation through recruitment of the ADA complex. In light of p53's dependence on the HAT activity of GCN5 for activation in yeast, it is noteworthy that the human homologues of GCN5 (hGCN5 and PCAF) also possess HAT activity. The HAT domain of hGCN5 can substitute for yeast GCN5 HAT domain in vivo (Wang et al., 1997) , suggesting that these proteins may function in similar transcriptional pathways in dierent organisms. Thus, it seems probable that human adaptors are involved in p53 function in human cells. The role of human adaptors (hADA2, hGCN5 and PCAF) in p53 transactivation in human cells is under current investigation. Curiously, a second tumor suppressor, BRCA1, which has an unknown mechanism of action, was found to interact with hGCN5 (Wu et al., 1996) . This interaction may provide novel insights into BRCA1 function in vivo.
Why are there multiple ASDs in p53, and both depend on the ADA pathway? It is possible that modi®cation of chromatin by acetylation is a ®rst and prerequisite step in transcriptional activation by p53, and subsequent mechanistic steps are dierent through ASD1 and ASD2. Since ASD2 activation is nearly totally dependent on the ADA pathway, perhaps the next mechanistic step is also through the ADA complex. In contrast, since ASD1 activation appears to have a ADA-dependent component and an ADAindependent component, perhaps the next step is direct interactions with basal transcription factors or with TAF coactivators.
Materials and methods
Yeast strains
The strains BGW17A (PinÄ a et al., 1993) and the trp1 7 derivatives of PSY316 and PSY316Dgcn5 have been described . The trp1 derivatives of PSY316Dada2 (Berger et al., 1992) , PSY316Dada3 (PinÄ a et al., 1993) where made as described previously .
Plasmids
Plasmids were constructed using standard procedures (Ausubel et al., 1994) . p53 deletion mutants used in this work are shown in Figure 1 .
To clone GAL4-p53 1-87 , p53 residues 1 ± 87 with a BglII restriction site at the 5' end and a NotI restriction site at the 3' end were ampli®ed by PCR. The resulting PCR fragment was cut with BglII/NotI and ligated into pPC97 (Chevray and Nathans, 1992). GAL4-p53 1 ± 40 was made by amplifying the p53 residues 1 ± 40 with a BglII restriction site at the 5' end and a BamHI restriction site at the 3' end. The PCR fragment, cut with BglII/BamHI, was ligated into pPC97 opened with BglII. GAL4-p53 40 ± 83 was made by PCR ampli®cation of p53 residues 40 ± 83 with a BglII restriction site at the 5' end and a EagI restriction site at the 3' end. The resulting fragment was cut with BglII/EagI and ligated into pPC97 opened with BglII/NotI. GAL4-p53 1-40D13-19 was made as described for GAL4-p53 1-40 but using p53D13 ± 19 as DNA p53 adaptor-dependent sub-activation domains R Candau et al template. GAL4-p53 1-83 was made by digestion of GAL4-p53 1-87 with EagI and insertion of a linker with stop codons. The high copy version of the GAL4-p53 1-87 fusion was made in three steps. First, pRS425 (Christianson et al., 1992) was cut with NotI, ®lled with the Klenow fragment of DNA polymerase I and self-ligated to destroy the NotI site. Second, the BamHI/ApaI fragment of pPC97 containing the ADH promoter and terminator was inserted into the BamHI/ApaI site of the resulting plasmid to make pPC97-2m. Third, pPC97-2m was opened with BglII/NotI and the PCR fragment of p53 with residues 1 ± 87 described above was inserted.
GAL4-VP16 413-490 high copy (Berger et al., 1992) and low copy (PinÄ a et al., 1993) , GAL4-VP16 470-490 low copy (Barlev et al., 1995) and GAL4-HAP4 high copy (Berger et al., 1992) have been described.
To construct pPC87-mdm-2, pPC87 was opened with NotI, ®lled with Klenow and then cut with EcoRI and the PvuII/EcoRI fragment of pGEM-mdm-2 containing mdm-2 was inserted.
Expression plasmids for GCN5 deletion mutants were described elsewhere Candau et al., 1997) . Expression plasmids for mammalian cells; GAL4-VP16 has been described . pcDNA3-GAL4-p53 1-87 , 1-40 and 40-83 was made by cutting GAL4-p53 1-87, 1-40 and 40-83 out of the yeast expression plasmids with NotI/HindIII (GAL4-p53 1-87 and 1-40 ) and EagI/HindIII (GAL4-p53 ), the fragments were gel isolated and inserted into pcDNA3 (Invitrogen) opened with NotI/HindIII.
The reporters used were pLGSD5 (Guarente et al., 1982) for yeast activation, pBLCAT2 (Luckow and Schultz, 1987) for Cos-7 cells and pBCTkSEAP for Saos cells. The latter plasmid is identical to pEP21TkSEAP (Waterman et al., 1996) , except that it contains a BC oligonucleotide as the p53-binding site.
Growth inhibition and b-gal assays
Growth inhibition by GAL4-VP16 was carried out in PSY316Dtrp1, PSY316Dtrp1Dada2, PSY316Dtrp1Dada3 or PSY316Dtrp1Dgcn5 transformed with the GAL4-VP16, GAL4-HAP4, GAL4-p53 1-87 high copy expression plasmids or vector alone, plated on SD minimal medium, and incubated at 308C for 3 days.
b-Gal assays (Rose et al., 1988) were carried out in PSY316trp1, PSY316trp1Dada2, PSY316Dtrp1Dada3 or PSY316Dtrp1Dgcn5 transformed with the plasmids described for each experiment. BGW17A was used to test the activity of the aa 1 ± 87 region of p53, since the full p53 activation domain was toxic PSY316. b-Gal activity was determined as units per mg protein.
Transient transfection experiment in mammalian cells, CAT assays and secreted alkaline phosphatase assays Transient transfection in Cos-7 cells were performed by the DEAE-Dextran method as described in . The CAT reporter plasmid was G5-E4-Tk-CAT (Carey et al., 1990) . CAT assays were performed as described previously (Ausubel et al., 1994) .
Transient transfections in Saos-2 cells were performed by the calcium phosphate method and the transcriptional activity of p53wt was quantitated using the pBCTkSEAP reporter plasmid as previously described (Waterman et al., 1996) .
